Brazilian strains of Toxoplasma gondii are controlled by azithromycin and modulate cytokine production in human placental explants

[1]  Lin Wang,et al.  Transcriptome Sequencing Investigated the Tumor-Related Factors Changes After T. gondii Infection , 2019, Front. Microbiol..

[2]  O. Martins-Filho,et al.  Azithromycin treatment is able to control the infection by two genotypes of Toxoplasma gondii in human trophoblast BeWo cells. , 2017, Experimental parasitology.

[3]  D. Correa,et al.  Is Toxoplasma gondii type related to clinical outcome in human congenital infection? Systematic and critical review , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[4]  N. M. Silva,et al.  Phenotypic and genotypic characterization of two Toxoplasma gondii isolates in free-range chickens from Uberlândia, Brazil , 2016, Epidemiology and Infection.

[5]  J. Schaefer,et al.  Toxoplasma gondii: history and diagnostic test development , 2015, Animal Health Research Reviews.

[6]  C. Su,et al.  Calomys callosus chronically infected by Toxoplasma gondii clonal type II strain and reinfected by Brazilian strains is not able to prevent vertical transmission , 2015, Front. Microbiol..

[7]  N. M. Silva,et al.  Azithromycin is able to control Toxoplasma gondii infection in human villous explants , 2014, Journal of Translational Medicine.

[8]  E. Ferro,et al.  Experimental infection of Calomys callosus with atypical strains of Toxoplasma gondii shows gender differences in severity of infection , 2014, Parasitology Research.

[9]  F. Ietta,et al.  Susceptibility to Toxoplasma gondii proliferation in BeWo human trophoblast cells is dose-dependent of macrophage migration inhibitory factor (MIF), via ERK1/2 phosphorylation and prostaglandin E2 production. , 2014, Placenta.

[10]  Xing-Quan Zhu,et al.  Geographical patterns of Toxoplasma gondii genetic diversity revealed by multilocus PCR-RFLP genotyping , 2013, Parasitology.

[11]  J. Wilczyński,et al.  Do the placental barrier, parasite genotype and Toll-like receptor polymorphisms contribute to the course of primary infection with various Toxoplasma gondii genotypes in pregnant women? , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[12]  N. M. Silva,et al.  Differential apoptosis in BeWo cells after infection with highly (RH) or moderately (ME49) virulent strains of Toxoplasma gondii is related to the cytokine profile secreted, the death receptor Fas expression and phosphorylated ERK1/2 expression. , 2013, Placenta.

[13]  G. Kaplan,et al.  Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis , 2013, Proceedings of the National Academy of Sciences.

[14]  C. Su,et al.  Genetic Characterization of Toxoplasma gondii Revealed Highly Diverse Genotypes for Isolates from Newborns with Congenital Toxoplasmosis in Southeastern Brazil , 2013, Journal of Clinical Microbiology.

[15]  A. Sanecka,et al.  Use and abuse of dendritic cells by Toxoplasma gondii , 2012, Virulence.

[16]  S. Robson,et al.  Effects of interleukin-6 on extravillous trophoblast invasion in early human pregnancy. , 2012, Molecular human reproduction.

[17]  C. Su,et al.  Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology , 2012, Parasitology.

[18]  A. Brunn,et al.  Neuronal gp130 expression is crucial to prevent neuronal loss, hyperinflammation, and lethal course of murine Toxoplasma encephalitis. , 2012, The American journal of pathology.

[19]  F. Robert-Gangneux,et al.  Epidemiology of and Diagnostic Strategies for Toxoplasmosis , 2012, Clinical Microbiology Reviews.

[20]  P. Zhou,et al.  Globally diverse Toxoplasma gondii isolates comprise six major clades originating from a small number of distinct ancestral lineages , 2012, Proceedings of the National Academy of Sciences.

[21]  H. Vardhan,et al.  Differing effects of azithromycin and doxycycline on cytokines in cells from Chlamydia trachomatis-infected women. , 2012, DNA and cell biology.

[22]  P. Deloron,et al.  Congenital parasitic infections: a review. , 2012, Acta tropica.

[23]  R. Molestina,et al.  Effects of Toxoplasma gondii genotype and absence of host MAL/Myd88 on the temporal regulation of gene expression in infected microglial cells. , 2011, Experimental parasitology.

[24]  A. Teixeira-Carvalho,et al.  Azithromycin and spiramycin induce anti-inflammatory response in human trophoblastic (BeWo) cells infected by Toxoplasma gondii but are able to control infection. , 2011, Placenta.

[25]  A. Kaye.  Toxoplasmosis: diagnosis, treatment, and prevention in congenitally exposed infants. , 2011, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.

[26]  D. Lindsay,et al.  Toxoplasma gondii: the changing paradigm of congenital toxoplasmosis , 2011, Parasitology.

[27]  Y. Ogiso,et al.  Fetal therapy of severe symptomatic toxoplasmosis using azithromycin , 2011, The journal of obstetrics and gynaecology research.

[28]  M. Roque-Barreira,et al.  Immunopathology and Infectious Diseases Effect of Macrophage Migration Inhibitory Factor ( MIF ) in Human Placental Explants Infected with Toxoplasma gondii Depends on Gestational Age , 2011 .

[29]  S. Katz,et al.  Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs , 2011 .

[30]  J. Saeij,et al.  Strain-specific activation of the NF-κB pathway by GRA15, a novel Toxoplasma gondii dense granule protein , 2011, The Journal of experimental medicine.

[31]  R. Yolken,et al.  Differential Effects of Three Canonical Toxoplasma Strains on Gene Expression in Human Neuroepithelial Cells , 2010, Infection and Immunity.

[32]  R. Gilbert,et al.  Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study , 2010, PLoS medicine.

[33]  B. Rubin,et al.  Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications , 2010, Clinical Microbiology Reviews.

[34]  U. Markert,et al.  ORIGINAL ARTICLE: Role of Regulatory and Angiogenic Cytokines in Invasion of Trophoblastic Cells , 2009, American journal of reproductive immunology.

[35]  D. Palm,et al.  Comparison of the AF146527 and B1 Repeated Elements, Two Real-Time PCR Targets Used for Detection of Toxoplasma gondii , 2009, Journal of Clinical Microbiology.

[36]  E. Ferro,et al.  Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae). , 2009, Placenta.

[37]  P. Zhou,et al.  Moving towards an integrated approach to molecular detection and identification of Toxoplasma gondii , 2009, Parasitology.

[38]  N. M. Silva,et al.  Apoptosis and S phase of the cell cycle in BeWo trophoblastic and HeLa cells are differentially modulated by Toxoplasma gondii strain types. , 2009, Placenta.

[39]  M. Demar,et al.  Severe Acquired Toxoplasmosis Caused by Wild Cycle of Toxoplasma gondii, French Guiana , 2009, Emerging infectious diseases.

[40]  J. Ajioka,et al.  Selection at a Single Locus Leads to Widespread Expansion of Toxoplasma gondii Lineages That Are Virulent in Mice , 2009, PLoS genetics.

[41]  R. Gilbert.  Treatment for congenital toxoplasmosis: finding out what works. , 2009, Memorias do Instituto Oswaldo Cruz.

[42]  M. Dardé.  Toxoplasma gondii, "new" genotypes and virulence. , 2008, Parasite.

[43]  J. Montoya,et al.  Management of Toxoplasma gondii infection during pregnancy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  R. Gilbert,et al.  Ocular Sequelae of Congenital Toxoplasmosis in Brazil Compared with Europe , 2008, PLoS neglected tropical diseases.

[45]  C. Su,et al.  Population structure and mouse-virulence of Toxoplasma gondii in Brazil. , 2008, International journal for parasitology.

[46]  H. Elsheikha.  Congenital toxoplasmosis: priorities for further health promotion action. , 2008, Public health.

[47]  M. Falagas,et al.  Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. , 2007, International journal of antimicrobial agents.

[48]  J. Boothroyd,et al.  Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue , 2007, Nature.

[49]  R. Gilbert,et al.  Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data , 2007, The Lancet.

[50]  C. Su,et al.  Genotyping of Toxoplasma gondii by multilocus PCR-RFLP markers: a high resolution and simple method for identification of parasites. , 2006, International journal for parasitology.

[51]  J. Boothroyd,et al.  Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host. , 2005, Trends in parasitology.

[52]  J. Tamaoki,et al.  Clinical implications of the immunomodulatory effects of macrolides. , 2004, The American journal of medicine.

[53]  B. Rubin.  Immunomodulatory properties of macrolides: overview and historical perspective. , 2004, The American journal of medicine.

[54]  J. Montoya,et al.  Toxoplasmosis , 2004, The Lancet.

[55]  C. Uyttenhove,et al.  Virulent Toxoplasma gondii strain RH promotes T-cell-independent overproduction of proinflammatory cytokines IL12 and gamma-interferon. , 2003, Journal of medical microbiology.

[56]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[57]  R. Gilbert,et al.  Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii , 2003, BJOG : an international journal of obstetrics and gynaecology.

[58]  Participants are listed on page.  Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. , 2003 .

[59]  L. Sibley,et al.  Acute Toxoplasmosis Leads to Lethal Overproduction of Th1 Cytokines1 , 2001, The Journal of Immunology.

[60]  J. Boothroyd,et al.  Unusual abundance of atypical strains associated with human ocular toxoplasmosis. , 2001, The Journal of infectious diseases.

[61]  J. Bernhagen,et al.  Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. , 1998, Journal of immunology.

[62]  C. Roberts,et al.  A protective role for IL‐6 during early infection with Toxoplasma gondii , 1998, Parasite immunology.

[63]  David S. Roos,et al.  A plastid organelle as a drug target in apicomplexan parasites , 1997, Nature.

[64]  S. Lye,et al.  Activin is a local regulator of human cytotrophoblast cell differentiation. , 1997, Endocrinology.

[65]  L. Sibley,et al.  Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. , 1995, The Journal of infectious diseases.

[66]  E. Pfefferkorn,et al.  Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin , 1994, Antimicrobial Agents and Chemotherapy.

[67]  T. Gomella.  Neonatology: Management, Procedures, On-Call Problems, Diseases, Drugs , 1992 .

[68]  Marissa Martinez Hampton.  Congenital Toxoplasmosis: A Review , 2015, Neonatal Network.

[69]  E. Bevilacqua,et al.  Macrophage migration inhibitory factor is up-regulated in human first-trimester placenta stimulated by soluble antigen of Toxoplasma gondii, resulting in increased monocyte adhesion on villous explants. , 2008, The American journal of pathology.

[70]  R. Gold,et al.  Interleukin-17--extended features of a key player in multiple sclerosis. , 2008, The American journal of pathology.

[71]  A. Hehl,et al.  Lipid biology of Apicomplexa: perspectives for new drug targets, particularly for Toxoplasma gondii. , 2006, Trends in parasitology.